– Late-breaking oral presentation to highlight 52-week data of ESK-001 in a Phase 2 open-label extension (OLE) study in adults with moderate-to-severe plaque psoriasis – – Additional Phase 2 e-poster ...

(RTTNews) - Alumis Inc. (ALMS) announced positive 52-week data from the open-label extension (OLE) of its Phase 2 STRIDE clinical trial evaluating ESK-001 in patients with moderate-to-severe plaque ...

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...

Across both STOP-HS1 and STOP-HS2, povorcitinib treatment resulted in continued clinically meaningful and statistically significant improvements for patients with active moderate to severe ...

NORTH CHICAGO, Ill., June 15, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive top-line results from COMMAND, its Phase 3 maintenance study, showing risankizumab (SKYRIZI ®, 180 mg or ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sinaptica Therapeutics, Inc., a clinical-stage company leading the development of a new class of personalized neuromodulation therapeutics to treat Alzheimer’s and ...

Post-hoc analyses corroborate previously reported antifibrotic effects of efruxifermin observed in 96-week Phase 2b SYMMETRY trial and indicate potential to reduce risk of disease progression in ...

Altimmune Inc (NASDAQ:ALT) shares are trading higher Monday after the company announced data from the 48-week Phase 2 MOMENTUM clinical trial of pemvidutide. What Happened: Altimmune said it presented ...

The MarketWatch News Department was not involved in the creation of this content. MariTide, the First Monthly or Less Frequently Dosed Obesity Treatment, Demonstrated Up to 20% Average Weight Loss ...

As a personal trainer and nutritionist, I have worked with numerous clients wanting to bulk up. Having more muscle can be advantageous for your aesthetics, overall health, and longevity. While it is ...